- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Shelton Today
By the People, for the People
NanoViricides Files Orphan Drug Designation for Measles Treatment
Potential incentives include tax credits, user fee exemptions, and market exclusivity if approved
Published on Feb. 10, 2026
Got story updates? Submit your updates here. ›
NanoViricides, Inc., a clinical-stage biotech company, has filed an application for Orphan Drug Designation (ODD) with the US FDA for its drug candidate NV-387 as a treatment for measles. If approved, ODD would provide the company with various incentives to support the regulatory development and approval of NV-387 as a much-needed treatment option for the growing measles outbreaks worldwide.
Why it matters
Measles cases have been rising globally, including in the US, with over 2,200 confirmed cases and 3 deaths in 2025. Vaccination rates have declined due to hesitancy, making an effective treatment crucial to combat the spread of this highly contagious disease and avoid severe complications like encephalitis and fatalities. NV-387 is the only known drug candidate that has demonstrated strong efficacy against lethal measles infection in animal studies, making it a potentially important tool to address the measles resurgence.
The details
NanoViricides filed the ODD application with the help of regulatory consultant Dr. Timothy Cote, former director of the FDA's Office of Orphan Products Development. If approved, ODD would provide the company with incentives like tax credits, user fee exemptions, and potential 7 years of market exclusivity after approval. NV-387 has shown promise as a broad-spectrum antiviral effective against various viruses including RSV, COVID, influenza, and monkeypox in addition to measles.
- Measles cases in the US reached 2,251 confirmed with 3 deaths in 2025, up from 285 in 2024 and 59 in 2023.
- As of February 5, 2026, 727 confirmed measles cases have already been reported in the US this year.
The players
NanoViricides, Inc.
A publicly traded, clinical-stage biotech company developing broad-spectrum antiviral drugs based on its proprietary nanomedicine technology.
Dr. Anil R. Diwan
President and Executive Chairman of NanoViricides, who stated that NV-387 would be an important tool to fight the measles resurgence if approved.
Dr. Timothy Cote
A regulatory consultant who previously served as the Director of the FDA's Office of Orphan Products Development and assisted NanoViricides in developing the ODD application.
What they’re saying
“NV-387, as an effective drug would be an important tool to fight Measles resurgence in the USA and worldwide, when approved.”
— Anil R. Diwan, PhD, President and Executive Chairman, NanoViricides
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
